Technically, Human Genome Sciences
The company recorded a measly $18.8 million in revenue from partnerships with GlaxoSmithKline
But don't let the nature of the (mostly) drugless biotech lull you to sleep. Like a good horror flick, there's something lurking in the woods, and it's going to send the stock moving in one direction or the other on the other side of Halloween.
On Monday, we'll get to hear the results from the second phase 3 trial of Benlysta in systemic lupus erythematosus (SLE) patients. The suspense has been growing since Human Genome and its partner Glaxo announced the release date a few weeks ago. It's rare that investors get more than an overnight warning of the release of phase 3 trial results. Usually companies want to get them out as soon as the data is compiled.
Just a few months ago, no one gave the drug much chance of working, but the first phase 3 trial was positive and the stock is up more than 500% since then. That success should give investors confidence that the second trial will work, but it doesn't guarantee success, as InterMune's
The risk of failure is also increased because Benlysta treats lupus -- the place where good drugs go to die. Biogen Idec
The way I see it, there's less upside potential than downside risk at this point, and I'll take a pass and watch from the sidelines while munching on leftover Halloween candy Monday morning.
Got a different take? Let us know in the comments box below.
BioMarin and InterMune are Motley Fool Rule Breakers recommendations. The newsletter team is always on the hunt for hot drug stocks and other cutting-edge picks. See all of our latest discoveries with a free 30-day trial.
Fool contributor Brian Orelli, Ph.D., buys the variety pack and then hands out all the candy he doesn't like first. He doesn't own shares of any company mentioned in this article. Novartis is a Global Gains selection. Despite eating a Snickers every day, the Fool's disclosure policy is never satisfied with protecting your interests.